Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GTI-2040 and Capecitabine in Advanced Renal Cell Carcinoma
NCT00056173Phase 2Completed
- Sponsor
- Aptose Biosciences Inc.
- Start
- Mar 2002
- Primary completion
- Dec 2004
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of GTI-2040 in renal cell carcinoma (RCC), sponsored by Aptose Biosciences Inc. Primary endpoints: Objective Response Rate and Maximum Tolerated Dose. Started Mar 2002; status: completed.
02
Drugs
GTI-2040
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00056173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00056173.